pSivida Corp. (PSDV)

2.22
0.06 2.42
NASDAQ : Health Technology
Prev Close 2.27
Open 2.26
Day Low/High 2.13 / 2.27
52 Wk Low/High 0.93 / 2.88
Volume 300.85K
Avg Volume 358.80K
Exchange NASDAQ
Shares Outstanding 45.16M
Market Cap 51.94M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
PSivida’s Partner Alimera Sciences Announces An Agreement To Raise Capital To Fund The Development And Commercialization Of ILUVIEN®

PSivida’s Partner Alimera Sciences Announces An Agreement To Raise Capital To Fund The Development And Commercialization Of ILUVIEN®

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its partner Alimera Sciences disclosed an ...

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

PSivida Corp. Announces Enrollment Of First Patient In Uveitis Trial

PSivida Corp. Announces Enrollment Of First Patient In Uveitis Trial

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the enrollment of the first patient in an ...

PSivida Corp. Announces Issuance Of US Patent For Inserter To Be Used In Planned Phase III Uveitis Trials

PSivida Corp. Announces Issuance Of US Patent For Inserter To Be Used In Planned Phase III Uveitis Trials

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced it has been issued US patent No.

PSivida Corp. Announces Portugal Grants ILUVIEN® Marketing Authorization For The Treatment Of Chronic Diabetic Macular Edema

PSivida Corp. Announces Portugal Grants ILUVIEN® Marketing Authorization For The Treatment Of Chronic Diabetic Macular Edema

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the National Authority of Medicines and Health...

PSivida Corp. Announces Expiration Of 2.7 Million Warrants

PSivida Corp. Announces Expiration Of 2.7 Million Warrants

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the expiration on May 15, 2012 of warrants to...

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade higher from current levels.

8 Stocks Under $10 Moving Higher

8 Stocks Under $10 Moving Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

PSivida Announces Second Tech Evaluation Agreement With Its BioErodible Durasert Technology

PSivida Announces Second Tech Evaluation Agreement With Its BioErodible Durasert Technology

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that it has entered into a technology evaluation...

PSivida Corp. Names Douglas Godshall To Board Of Directors

PSivida Corp. Names Douglas Godshall To Board Of Directors

pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has elected Douglas Godshall to its Board of...

PSivida Corp. Announces Positive Outcome To European Decentralized Procedure For Approval Of ILUVIEN® For The Treatment Of Chronic Diabetic Macular Edema

PSivida Corp. Announces Positive Outcome To European Decentralized Procedure For Approval Of ILUVIEN® For The Treatment Of Chronic Diabetic Macular Edema

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the positive outcome of the Decentralized Procedure...

5 Stocks Under $5 Making Big Moves

5 Stocks Under $5 Making Big Moves

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

PSivida Corp. Reports Results For The Second Quarter Ended December 31, 2011

PSivida Corp. Reports Results For The Second Quarter Ended December 31, 2011

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its second quarter ended...

PSivida CEO To Present At 14th Annual BioCEO & Investor Conference February 14

PSivida CEO To Present At 14th Annual BioCEO & Investor Conference February 14

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its President and CEO, Dr.

PSivida CEO To Participate In Panel At Glaucoma 360 Conference February 3

PSivida CEO To Participate In Panel At Glaucoma 360 Conference February 3

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its President and CEO, Dr.

PSivida Corp Announces Second Quarter 2012 Financial Results Release Date And Conference Call Information

PSivida Corp Announces Second Quarter 2012 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the second quarter of...

PSivida Announces Tech Evaluation Agreement With Leading Pharmaceutical Company

PSivida Announces Tech Evaluation Agreement With Leading Pharmaceutical Company

pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that it has signed a funded technology evaluation...

PSivida Corp. To Hold Monday November 14 Conference Call To Discuss Complete Response Letter For ILUVIEN® For DME And PSivida’s Product Pipeline

PSivida Corp. To Hold Monday November 14 Conference Call To Discuss Complete Response Letter For ILUVIEN® For DME And PSivida’s Product Pipeline

pSivida Corp. (NASDAQ:PSDV, ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that it will host a live webcast and conference call...

PSivida Reports Receipt By Alimera Sciences Of Complete Response Letter From FDA For ILUVIEN® For DME

PSivida Reports Receipt By Alimera Sciences Of Complete Response Letter From FDA For ILUVIEN® For DME

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today reported that its licensee Alimera Sciences, Inc.

PSivida Corp. Reports Results For The First Quarter Ended September 30, 2011

PSivida Corp. Reports Results For The First Quarter Ended September 30, 2011

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its first quarter ended...

Biotech Calendar: Key Dates for November

Biotech Calendar: Key Dates for November

Here's a list of November's potentially stock-moving biotech events.

PSivida Corp. Announces First Quarter 2012 Financial Results Release Date And Conference Call Information

PSivida Corp. Announces First Quarter 2012 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the first quarter of...

PSivida Ranked 59th Fastest Growing Company In North America On Deloitte’s 2011 Technology Fast 500™

PSivida Ranked 59th Fastest Growing Company In North America On Deloitte’s 2011 Technology Fast 500™

Drug delivery company pSivida Corp. (NASDAQ:PSDV)(ASX:PVA) today announced it ranked 59th on the Deloitte 2011 Technology Fast 500™, ranking of the 500 fastest growing technology, media, telecommunications, life...

PSivida Corp. Reports Fourth Quarter And Fiscal Year 2011 Results

PSivida Corp. Reports Fourth Quarter And Fiscal Year 2011 Results

pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including clinical stage product candidates for the treatment of...

PSivida Announces Opening Of Investigator-Sponsored Trial For Injectable, Sustained Release FAc Insert For Posterior Uveitis

PSivida Announces Opening Of Investigator-Sponsored Trial For Injectable, Sustained Release FAc Insert For Posterior Uveitis

Drug delivery company pSivida Corp. (NASDAQ:PSDV) (ASX:PVA) today announced the opening of an investigational new drug application (IND) for a Phase I/II clinical trial to study pSivida’s injectable, sustained ...

PSivida To Webcast Presentation At Rodman & Renshaw Health Care Conference

PSivida To Webcast Presentation At Rodman & Renshaw Health Care Conference

pSivida Corp, (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that it will webcast its live...

PSivida Corp Announces Fourth Quarter And Fiscal Year 2011 Financial Results Release Date And Conference Call Information

PSivida Corp Announces Fourth Quarter And Fiscal Year 2011 Financial Results Release Date And Conference Call Information

pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the fourth quarter and...

PSivida Announces An Evaluation Agreement With Hospital For Special Surgery To Investigate Bioerodible Sustained Release Systems In Orthopedic Surgery

PSivida Announces An Evaluation Agreement With Hospital For Special Surgery To Investigate Bioerodible Sustained Release Systems In Orthopedic Surgery

Drug delivery company pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) today announced it has entered into an evaluation agreement with Hospital for Special Surgery (HSS), a world leader in orthopedics, rheumatology and ...

PSivida CEO To Present On Company Technologies At Three Conferences In June

PSivida CEO To Present On Company Technologies At Three Conferences In June

pSivida Corp., (NASDAQ:PSDV)(ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, including the product candidate ILUVIEN® for the treatment of ...

PSivida Announces Phase I/II Clinical Study Evaluating Bioerodible, Sustained Release Latanoprost Device In Ocular Hypertension And Glaucoma

PSivida Announces Phase I/II Clinical Study Evaluating Bioerodible, Sustained Release Latanoprost Device In Ocular Hypertension And Glaucoma

Drug delivery company pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) today announced the commencement of a Phase I/II clinical trial studying a new bioerodible drug delivery implant for the treatment of glaucoma and ocular...